| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,500,000 |
| Market
Cap: |
1.09(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22.99 - $53.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,500 |
6,731 |
78,647 |
660,289 |
| Total Sell Value |
$39,066 |
$183,567 |
$3,529,022 |
$35,647,507 |
| Total People Sold |
1 |
2 |
5 |
8 |
| Total Sell Transactions |
3 |
5 |
15 |
42 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-06-13 |
4 |
OE |
$13.03 |
$2,606,000 |
D/D |
200,000 |
2,847,659 |
|
- |
|
| Lee Howard |
|
– • – |
2025-06-03 |
4 |
D |
$26.01 |
$24,007 |
D/D |
(923) |
151,976 |
|
- |
|
| Lee Howard |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
152,899 |
|
- |
|
| Zasloff Michael A |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
29,524 |
|
- |
|
| Deflin Gayle |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
10,914 |
|
- |
|
| Prins Richard K |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
35,183 |
|
- |
|
| Gerst Diane G. |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
23,756 |
|
- |
|
| Petersen Floyd F. |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,122 |
78,031 |
|
- |
|
| Petersen Floyd F. |
|
– • – |
2025-06-02 |
4 |
AS |
$25.67 |
$12,835 |
D/D |
(500) |
72,909 |
|
-9% |
|
| Peters William J |
CFO, EVP & TREASURER |
• • – |
2025-05-19 |
4 |
D |
$24.79 |
$6,768 |
D/D |
(273) |
124,985 |
|
- |
|
| Petersen Floyd F. |
|
– • – |
2025-05-01 |
4 |
AS |
$24.08 |
$12,041 |
D/D |
(500) |
73,409 |
|
-3% |
|
| Petersen Floyd F. |
|
– • – |
2025-04-01 |
4 |
AS |
$28.38 |
$14,190 |
D/D |
(500) |
73,909 |
|
-18% |
|
| Peters William J |
CFO, EVP & TREASURER |
• • – |
2025-03-17 |
4 |
D |
$27.69 |
$83,181 |
D/D |
(3,004) |
125,258 |
|
- |
|
| Liawatidewi Yakob |
EVP CORP ADMIN CENTER |
• • – |
2025-03-17 |
4 |
D |
$27.69 |
$47,931 |
D/D |
(1,731) |
90,909 |
|
- |
|
| Zhou Rong |
SENIOR EVP, PRODUCTION CENTER |
• – – |
2025-03-17 |
4 |
D |
$27.69 |
$54,466 |
D/D |
(1,967) |
137,497 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-17 |
4 |
D |
$27.69 |
$200,005 |
I/I |
(7,223) |
1,185,475 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-17 |
4 |
D |
$27.69 |
$447,194 |
D/D |
(16,150) |
2,647,659 |
|
- |
|
| Peters William J |
CFO, EVP & TREASURER |
• • – |
2025-03-15 |
4 |
D |
$26.66 |
$52,467 |
D/D |
(1,968) |
128,262 |
|
- |
|
| Liawatidewi Yakob |
EVP CORP ADMIN CENTER |
• • – |
2025-03-15 |
4 |
D |
$26.66 |
$27,486 |
D/D |
(1,031) |
92,640 |
|
- |
|
| Zhou Rong |
SENIOR EVP, PRODUCTION CENTER |
• – – |
2025-03-15 |
4 |
D |
$26.66 |
$32,579 |
D/D |
(1,222) |
139,464 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-15 |
4 |
D |
$26.66 |
$109,706 |
I/I |
(4,115) |
1,192,698 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-15 |
4 |
D |
$26.66 |
$260,335 |
D/D |
(9,765) |
2,663,809 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-14 |
4 |
D |
$26.66 |
$4,336,436 |
I/I |
(162,657) |
1,196,813 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-14 |
4 |
OE |
$14.69 |
$3,102,719 |
I/I |
211,213 |
1,359,470 |
|
- |
|
| Luo Mary Z. |
COO, Chief Scientist, Chairman |
• • • |
2025-03-14 |
4 |
D |
$26.66 |
$6,032,758 |
D/D |
(226,285) |
2,673,574 |
|
- |
|
922 Records found
|
|
Page 1 of 37 |
|
|
0.12 (0.52%) 
